MeiraGTx
Develops locally delivered AAV gene therapies and manufactures its own viral vectors.
Something off on this page? Send us feedback.
Profile
Develops AAV-based gene therapies for eye, brain and salivary-gland disease, paired with a riboswitch platform that lets patients control transgene activity with an oral pill. Vector and plasmid manufacturing happen in owned GMP plants rather than through outside contractors, an unusual setup for a company at this stage.
Builds gene therapies delivered locally to the eye, central nervous system and salivary glands using adeno-associated virus vectors, paired with a riboswitch technology that turns transgene expression on and off with an oral pill.
Manufacturing stays in-house at owned GMP-licensed viral-vector and plasmid plants in London and Shannon, Ireland, rather than outsourced to contract manufacturers, a structure most peers its size do not attempt.
No product has reached approval yet, so revenue comes from collaboration and licensing payments tied to partnered programs, including a major pharmaceutical partner and a joint venture funding late-stage neurology and metabolic-disease work. Corporate operations sit in New York; research and manufacturing sit in the UK and Ireland.
A lead retinal-disease program was sold to a partner and later reacquired after a late-stage trial missed its primary goal, with regulatory filings now planned in multiple markets.
Company facts
Key statistics
Year to date +77.0% · Average volume (30d) 585.3K
Analysts
Ratings
Target range
Latest analyst notes
| Date | Firm | Action | Rating | Prior target | Target |
|---|---|---|---|---|---|
| Jul 8, 2026 | RBC Capital | Reiterate | Outperform | $24 | $26 |
| Apr 17, 2026 | RBC Capital | Reiterate | Outperform | $16 | $24 |
| Mar 27, 2026 | Piper Sandler | Reiterate | Overweight | $26 | |
| Nov 24, 2025 | H.C. Wainwright | Target | $20 | ||
| Nov 14, 2025 | RBC Capital | Reiterate | Outperform | $9 | $16 |
Earnings
EPS
Revenue
History
| Report date | EPS est | EPS | Surprise | Revenue est | Revenue | Surprise | Next session |
|---|---|---|---|---|---|---|---|
| Aug 13, 2026Q2 FY26 | −$0.46 | $1.71 | +473.1% | $700.0K | $321.4M | +45,819.1% | −2.24% |
| May 14, 2026Q1 FY26 | −$0.43 | −$0.57 | −32.6% | $17.0M | $293.0K | −98.3% | −5.53% |
| Mar 26, 2026Q4 FY25 | −$0.60 | $0.19 | +131.7% | $1.4M | $75.4M | +5,115.3% | +1.20% |
| Nov 13, 2025Q3 FY25 | −$0.50 | −$0.62 | −24.0% | $3.9M | $410.0K | −89.4% | −0.85% |
Financial highlights
| 12 quarters | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | |
|---|---|---|---|---|---|---|---|
| Revenue | $1.9M | $3.7M | $410.0K | $75.4M | $293.0K | $321.4M | |
| Gross profit | $548.0K | $1.0M | $97.0K | $74.9M | −$2.9M | $314.3M | |
| Operating income | −$41.6M | −$44.8M | −$46.1M | $26.5M | −$40.8M | $244.4M | |
| Net income | −$40.0M | −$38.8M | −$50.5M | $15.1M | −$46.3M | $160.7M | |
| Diluted EPS | −$0.51 | −$0.48 | −$0.62 | $0.19 | −$0.57 | $1.71 | |
| Gross margin | 28.5% | 27.5% | 23.7% | 99.4% | -994.2% | 97.8% | |
| Operating margin | -2,159.7% | -1,213.6% | -11,232.0% | 35.1% | -13,930.7% | 76.0% |
Fiscal years (4-quarter sums)FY21 $37.7M · FY22 $15.9M · FY23 $14.0M · FY24 $33.3M · FY25 $81.4M
Revenue by product · Q2 FY26
Balance sheet, Jun 30, 2026Cash & short-term investments $143.2M · Total debt $112.3M · Total assets $396.4M · Shareholders' equity $215.6M
Dividends
No dividends on record.
Ownership
Institutions and insiders are filed separately and overlap, so together they can pass the whole company. No split is drawn from them.
Shares outstanding 92.61M · Float 70.14M · 75.7% free float
Top shareholders13F · 13D/G · Form 4
| Holder | Shares | % outstanding | Form | Filed |
|---|---|---|---|---|
| Sanofi | 12.20M | 13.17% | 13F | Jul 28, 2026 |
| Perceptive Advisors LLC | 10.79M | 11.65% | 13F | Aug 14, 2026 |
| Rubric Capital Management LP | 9.10M | 9.83% | 13F | Aug 14, 2026 |
| Johnson & Johnson | 6.64M | 7.17% | 13F | Aug 6, 2026 |
| BlackRock, Inc. | 4.76M | 5.14% | 13F | Aug 7, 2026 |
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| Aug 18, 2026 | Alexandria Forbes | director, officer: PRESIDENT & CEO | −62,000 | $13.86 |
| Jul 21, 2026 | Richard Giroux | officer: CFO & COO | −56,000 | $12.51 |
| Jul 7, 2026 | Stuart Naylor | officer: CHIEF SCI OFCR, OPHTHALMOLOGY | −27,659 | $14.80 |
| May 19, 2026 | Alexandria Forbes | director, officer: PRESIDENT & CEO | −62,000 | $9.17 |
| Apr 21, 2026 | Richard Giroux | officer: CFO & COO | −56,000 | $10.22 |
Peers
- uniQure
Rival CNS AAV gene therapy leader; abandoned the vertical-manufacturing model.
- REGENXBIO
AAV vector platform licensor and direct ocular AAV rival with own manufacturing.
- Voyager Therapeutics
CNS AAV capsid rival with a partnered Parkinson's gene therapy program.
- Sarepta Therapeutics
Commercial AAV gene therapy leader in Duchenne; bellwether on AAV safety.
- 4D Molecular Therapeutics
Rival AAV capsid platform; former program shared the same RPGR gene target.
- Ocugen
Gene-agnostic AAV therapy for RP racing toward the same XLRP patients.
- Krystal Biotech
Commercial redosable gene therapy peer with a growing ocular pipeline.
CompareAfter-hours close
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| MeiraGTx | $13.82 | 0.00% | $1.28B | 19.5 | — | 3.2 | +8,608.6% |
| uniQure | $49.46 | +1.55% | $3.38B | — | — | 181.0 | +11.0% |
| REGENXBIO | $9.65 | −0.21% | $499.4M | — | — | 2.9 | +405.7% |
| Voyager Therapeutics | $3.53 | −0.28% | $213.9M | — | — | 6.2 | −39.1% |
| Sarepta Therapeutics | $21.05 | +0.98% | $2.20B | — | 26.3 | 1.1 | −34.3% |
| 4D Molecular Therapeutics | $14.67 | +0.07% | $766.9M | — | — | 8.3 | +25,106.7% |
| Ocugen | $1.35 | +2.27% | $447.6M | — | — | 97.7 | +8.4% |
| Krystal Biotech | $351.46 | +0.05% | $10.36B | 44.0 | 41.3 | 23.5 | +24.1% |
| Median | 44.0 | 33.8 | 8.3 | +11.0% |